氯沙坦钾片联合百令胶囊治疗慢性肾脏病的临床研究#br#

doi:10.3969/j.issn.1007-3205.2019.10.005

河北医科大学学报

氯沙坦钾片联合百令胶囊治疗慢性肾脏病的临床研究#br#

1.承德医学院附属医院药学部，河北承德 067000；2.河北省平泉市妇幼保健院中医科，河北平泉 067500

出版日期:2019-10-25 发布日期:2019-10-21
作者简介:于文会(1981-)，女，河北平泉人，承德医学院附属医院主管药师，理学学士，从事临床药学研究。
基金资助:
承德市科技支撑计划(201701A064)

Clinical study of losartan potassium tablets combined with Bailing capsule in the treatment of chronic renal disease#br#

1.Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Hebei Province, Chengde
067000, China; 2.Department of Traditional Chinese Medicine, Pingquan Maternal and
Child Health Hospital, Hebei Province, Pingquan 067500， China

Online:2019-10-25 Published:2019-10-21

摘要/Abstract

摘要： 〗［摘要］
〖HTH〗目的〖HTSS〗观察氯沙坦钾片联合百令胶囊治疗慢性肾脏病的临床效果。
〖HTH〗方法〖HTSS〗将160例肾病患者随机分成4组各40例，分别为对照组、氯沙坦组、百令胶囊组及联合用药组。对照组采用控制饮食、控制血压以及维持水、电解质、酸碱平衡等对症治疗；氯沙坦组氯给予沙坦钾片50 mg/次,1次/d；百令胶囊组给予百令胶囊2.0 g/次，3次/d；联合用药组同时给予上述剂量的氯沙坦钾片及百令胶囊。治疗时间6个月，评估治疗效果，治疗前后分别检测肾功能指标血肌酐(serum creatinine，SCr)、尿素氮(blood ure Nitrogen，BUN)、24 h尿蛋白定量以及炎性因子白细胞诱素1(leukotactin-1，Lkn-1)、血管内皮生长因子(vascular endothelial growth factor，VEGF)、超敏C反应蛋白(high sensitive C-reaction protein，hs-CRP)、肿瘤坏死因子α(tumor necrosis factor-α，TNF-α)、白细胞介素18(interleukin-18，IL-18)等。
〖HTH〗结果〖HTSS〗氯沙坦组、百令胶囊组及联合用药组总体疗效均优于对照组，且联合用药组总体临床疗效优于百令胶囊组和氯沙坦组，差异有统计学意义（P＜0.05）；联合用药组与单一使用百令胶囊组和氯沙坦组相比较，治疗后SCr、BUN及24 h尿蛋白定量下降水平更为显著，差异有统计学意义（P＜0.05）；治疗后血清炎性因子Lkn-1、VEGF、hs-CRP、TNF-α及IL-18水平变化，联合用药组下降水平显著高于单一使用百令胶囊组和氯沙坦组，差异有统计学意义（P＜0.05）。
〖HTH〗结论〖HTSS〗联合应用氯沙坦钾片和百令胶囊治疗慢性肾脏病，可以减轻尿蛋白，减少BUN、SCr含量，改善肾功能，减轻肾小球硬化，延缓肾纤维化，有效改善肾功能指标和炎性因子水平。

关键词: 肾功能衰竭, 慢性；肾小球肾炎；氯沙坦钾；百令胶囊

Abstract: ［Abstract］ Objective〖HTSS〗To observe the clinical efficacy of losartan potassium tablets combined with Bailing capsules in the treatment of chronic kidney disease.
〖HTH〗〖WTHZ〗Methods〖HTSS〗160 patients with nephropathy were randomly divided into four groups: control group, losartan group, Bailing capsule group and combined drug group. The control group was given symptomatic treatment by controlling diet, controlling blood pressure and maintaining water, electrolyte and acid-base balance; the losartan group was given losartan potassium tablets 50 mg/time, once a day; the Bailing capsule group was given Bailing capsules 2.0 g/time, three times a day; the combined drug group was given losartan and Bailing capsules at the same time. The treatment lasted 6 months. Serum creatinine(SCr), blood urea nitrogen(BUN), 24 hour urinary protein quantification and inflammatory factor levels of leukotropin-1(Lknactin-1) and vascular endothelial growth factor(vascular endothelial growth factor) were measured before and after treatment. Vascular growth factor, high sensitive C-reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α) and interleukin-18(IL-18) were detected.
〖HTH〗〖WTHZ〗Results〖HTSS〗The overall efficacy of losartan group, Bailing capsule group and combined drug group was higher than that of control group, and the overall clinical efficacy of combined drug group was higher than that of Bailing capsule group and losartan group, with statistical significance(P＜0.05); renal function index of combined drug group was compared with that of single Bailing capsule and losartan group, after treatment, SCr, BUN After treatment, the levels of serum inflammatory factors Lkn-1, VEGF, hs-CRP, TNF-alpha and IL-18 were significantly higher in the combined group than those in the single Bailing capsule group and losartan group(P＜0.05).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗The combination of losartan potassium tablet and Bailing capsule can reduce urinary protein, BUN and SCr content, improve renal function, relieve glomerulosclerosis, effectively delay renal fibrosis, effectively improve renal function index and inflammatory factor level.

Key words: kidneyfailure, chronic, glomerulonephritis, losartan potassium, Bailing capsules

于文会1，段书众1*，于再学2，李丽静1. 氯沙坦钾片联合百令胶囊治疗慢性肾脏病的临床研究#br#[J]. 河北医科大学学报, doi: 10.3969/j.issn.1007-3205.2019.10.005.

YU Wen-hui1， DUAN Shu-zhong1*， YU Zai-xue2， LI Li-jing1. Clinical study of losartan potassium tablets combined with Bailing capsule in the treatment of chronic renal disease#br#[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.1007-3205.2019.10.005.

[1]	高艳玲. HFHD联合西沙必利对慢性CRF患者的炎症因子、肾功能指标及临床疗效分析[J]. 河北医科大学学报, 2022, 43(8): 909-914.
[2]	黄玉哲1，刘丽霞2，邱雨童3，金〓铂4，尹立勇5*. 红景天苷对慢性肾衰竭大鼠保护作用机制的研究#br#[J]. 河北医科大学学报, 2019, 40(8): 882-885,910.
[3]	刘双庆1，李〓娟2，宁〓莉1，曹〓阳1，魏殿军1*. 自身抗体与慢性肾衰竭老年患者临床相关性分析[J]. 河北医科大学学报, 2017, 37(8): 941-944.
[4]	杨〓艳，丁发贤，马〓潇，郭俊含，王沁园，王〓静*. 对慢性肾脏病患者个体化目标营养管理的调查分析[J]. 河北医科大学学报, 2017, 37(5): 525-528,534.
[5]	王洁;王菲. 慢性肾衰竭患者透析遵医行为的影响因素分析[J]. , 2014, 35(8): 882-882.
[6]	苏铁柱;白惠;幺文博. 糖尿病性肾衰竭患者动静脉内瘘37例手术体会[J]. , 2012, 33(11): 1313-1313.
[7]	刘华;刘翠兰;闫志云;郭立峰. 透析治疗对糖尿病肾衰竭顽固性高血压的影响[J]. , 2012, 33(10): 1211-1211.
[8]	陈如明. 血液透析治疗急性肾功能衰竭的临床研究[J]. , 2011, 32(5): 572-572.
[9]	张洁;任士卿. 以慢性肾功能衰竭为首发表现的高血压脑干脑病1例[J]. , 2011, 32(3): 295-295.
[10]	李同妙;常立欣;刘兰;张冬雪;王洋. 甲状旁腺全切加前臂自体移植治疗慢性肾功能衰竭患者继发性甲状旁腺功能亢进的疗效观察[J]. , 2011, 32(10): 1211-1211.
[11]	王翊飞;吴建祥. 重型颅脑外伤合并急性肾功能损伤危险因素分析[J]. , 2010, 31(7): 759-759.
[12]	黎红;贾世隆;粟显才;龙健猷. 辛伐他汀对冠心病合并肾功能不全患者肾功能的影响[J]. , 2009, 30(9): 872-872.
[13]	孟惠茹;张玉想;姜玲玲. 血必净对内毒素血症小鼠血浆内皮素-1及肾损害的影响[J]. , 2008, 29(3): 353-353.
[14]	王军;刁春华;张光宇. 输尿管镜下气压弹道碎石治疗肾后性肾功能衰竭(附18例报告)[J]. , 2008, 29(1): 45-45.
[15]	谭家庆;丁春华. HO/CO系统对内毒素致肾脏损伤保护作用的研究进展[J]. , 2006, 27(1): 53-53.

氯沙坦钾片联合百令胶囊治疗慢性肾脏病的临床研究#br#

Clinical study of losartan potassium tablets combined with Bailing capsule in the treatment of chronic renal disease#br#

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价